Barinthus Biotherapeutics (BRNS) Competitors $1.19 -0.05 (-4.03%) Closing price 03:59 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. SXTC, DERM, TVGN, CYBN, ACRS, LFVN, CCCC, VYGR, GLSI, and CTNMShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), Semper Paratus Acquisition (TVGN), Cybin (CYBN), Aclaris Therapeutics (ACRS), Lifevantage (LFVN), C4 Therapeutics (CCCC), Voyager Therapeutics (VYGR), Greenwich LifeSciences (GLSI), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors China SXT Pharmaceuticals Journey Medical Semper Paratus Acquisition Cybin Aclaris Therapeutics Lifevantage C4 Therapeutics Voyager Therapeutics Greenwich LifeSciences Contineum Therapeutics Barinthus Biotherapeutics (NASDAQ:BRNS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Is BRNS or SXTC more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -54.70% -44.75% China SXT Pharmaceuticals N/A N/A N/A Which has more risk and volatility, BRNS or SXTC? Barinthus Biotherapeutics has a beta of -0.73, meaning that its stock price is 173% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Do analysts recommend BRNS or SXTC? Barinthus Biotherapeutics currently has a consensus target price of $3.00, indicating a potential upside of 152.10%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, BRNS or SXTC? China SXT Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M3.21-$61.07M-$1.73-0.69China SXT Pharmaceuticals$1.74M106.03-$3.30MN/AN/A Does the media favor BRNS or SXTC? In the previous week, Barinthus Biotherapeutics and Barinthus Biotherapeutics both had 1 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 0.80 beat China SXT Pharmaceuticals' score of 0.43 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Positive China SXT Pharmaceuticals Neutral Do institutionals and insiders believe in BRNS or SXTC? 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryBarinthus Biotherapeutics beats China SXT Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.02M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.09%P/E RatioN/A20.7930.8625.29Price / Sales3.21232.07402.9888.13Price / CashN/A41.5625.2228.45Price / Book0.379.749.516.00Net Income-$61.07M-$54.74M$3.26B$265.34M7 Day Performance4.39%8.13%4.49%2.76%1 Month Performance-20.54%7.73%5.21%1.49%1 Year Performance-4.80%18.07%31.91%25.38% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.6844 of 5 stars$1.19-4.0%$3.00+152.1%+0.4%$50.02M$14.97M0.00107News CoverageShort Interest ↑Gap UpSXTCChina SXT Pharmaceuticals0.4009 of 5 stars$1.59+0.3%N/A-80.3%$183.90M$1.74M0.0090Short Interest ↑Gap UpDERMJourney Medical1.7099 of 5 stars$8.54+8.5%$9.50+11.2%+56.9%$183.34M$56.13M0.0090News CoverageEarnings ReportAnalyst RevisionHigh Trading VolumeTVGNSemper Paratus Acquisition3.7491 of 5 stars$0.96-1.8%$10.00+939.0%+35.5%$180.22MN/A0.003News CoverageAnalyst ForecastCYBNCybin2.4294 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$179.99MN/A-1.7450News CoveragePositive NewsACRSAclaris Therapeutics2.4404 of 5 stars$1.64flat$8.71+431.4%+57.1%$177.66M$18.72M0.00100LFVNLifevantage4.1298 of 5 stars$14.16+2.9%$30.50+115.4%+68.0%$173.21M$200.16M17.87260CCCCC4 Therapeutics1.7927 of 5 stars$2.24-7.4%$8.00+257.1%-57.9%$172.23M$35.58M0.00150VYGRVoyager Therapeutics3.6957 of 5 stars$3.39+10.1%$13.25+290.8%-42.3%$170.84M$80M0.00100GLSIGreenwich LifeSciences1.3727 of 5 stars$12.35-1.1%$39.00+215.8%-12.5%$166.97MN/A0.003Earnings ReportCTNMContineum Therapeutics3.2981 of 5 stars$6.75+5.0%$22.50+233.3%-56.9%$166.35M$50M0.0031News CoverageAnalyst ForecastShort Interest ↓ Related Companies and Tools Related Companies SXTC Competitors DERM Competitors TVGN Competitors CYBN Competitors ACRS Competitors LFVN Competitors CCCC Competitors VYGR Competitors GLSI Competitors CTNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access